Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hugel Inc.
Industry Sector: HealthTechnology
CEO: Ji-Hoon Sohn, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 27.55
Exchange/Ticker 1: KOSDAQ:145020
Exchange/Ticker 2: N/A
Latest Market Cap: $2,494,269,635
BioCentury | Apr 3, 2024
Data Byte
Last minute flurry brings FDA’s first-quarter NME approvals to 10
Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive
BioCentury | Mar 13, 2024
Data Byte
NME approvals off to slow start in 2024
FDA has approved just three NMEs so far this year, down from 10 at this time in 2023
BioCentury | Mar 12, 2021
Product Development
Korea Spotlight: How OliX is spreading its siRNA beyond Korea’s borders
New mRNA unit is the biotech’s latest bid to realize its global ambitions
Items per page:
1 - 3 of 3